OBJECTIVE: Molecular and environmental co-factors are known risk factors for cervical cancer. The aim of this study was to define the prognostic significance of HPV 18 and its phylogenetically related viruses and smoking on survival in patients with early stage cervical cancer. METHODS: HPV typing was performed on stage IB-IIB cervical tumors. Subjects positive for HPV 18 or 45 were compared to the remainder of the cohort and to women with tumors containing HPV 16, 31, or 52. Tobacco use was ascertained by patient questionnaire. RESULTS: Tumors of 255 women were evaluated. The presence of HPV 18 or 45 was associated with decreased survival. In a multivariable Cox proportional hazards analysis comparing patients with HPV 18 or 45 containing tumors to the rest of the cohort, the hazard ratio for death from cervical cancer was 2.08 (95% CI, 1.07-4.04). The hazard ratio for death from cervical cancer was 2.41 (95% CI, 1.17-4.96) when the HPV 18 and 45 group was compared to women with HPV 16 or its related viruses, 31 and 52. Smoking was associated with a decreased survival for women with HPV 18 or 45, even after adjusting for other known prognostic factors (P = 0.031). CONCLUSIONS: In addition to pathologic indicators, molecular and environmental co-factors are important determinates of outcome in early stage cervical cancer. The presence of HPV 18 or 45 is associated with a decreased survival. The adverse effect of HPV 18 and 45 on survival is compounded by tobacco use.
OBJECTIVE: Molecular and environmental co-factors are known risk factors for cervical cancer. The aim of this study was to define the prognostic significance of HPV 18 and its phylogenetically related viruses and smoking on survival in patients with early stage cervical cancer. METHODS: HPV typing was performed on stage IB-IIB cervical tumors. Subjects positive for HPV 18 or 45 were compared to the remainder of the cohort and to women with tumors containing HPV 16, 31, or 52. Tobacco use was ascertained by patient questionnaire. RESULTS:Tumors of 255 women were evaluated. The presence of HPV 18 or 45 was associated with decreased survival. In a multivariable Cox proportional hazards analysis comparing patients with HPV 18 or 45 containing tumors to the rest of the cohort, the hazard ratio for death from cervical cancer was 2.08 (95% CI, 1.07-4.04). The hazard ratio for death from cervical cancer was 2.41 (95% CI, 1.17-4.96) when the HPV 18 and 45 group was compared to women with HPV 16 or its related viruses, 31 and 52. Smoking was associated with a decreased survival for women with HPV 18 or 45, even after adjusting for other known prognostic factors (P = 0.031). CONCLUSIONS: In addition to pathologic indicators, molecular and environmental co-factors are important determinates of outcome in early stage cervical cancer. The presence of HPV 18 or 45 is associated with a decreased survival. The adverse effect of HPV 18 and 45 on survival is compounded by tobacco use.
Authors: Janet S Rader; Shirng-Wern Tsaih; Daniel Fullin; Miriam W Murray; Marissa Iden; Michael T Zimmermann; Michael J Flister Journal: Int J Cancer Date: 2019-01-04 Impact factor: 7.396
Authors: Hannah P Yang; David K Walmer; Delson Merisier; Julia C Gage; Laura Bell; Sameera Rangwala; Niwashin Shrestha; Lori Kobayashi; Paul S Eder; Philip E Castle Journal: J Virol Methods Date: 2011-05-27 Impact factor: 2.014
Authors: Xiaoxia Hu; Zhengyan Zhang; Duanduan Ma; Phyllis C Huettner; L Stewart Massad; Loan Nguyen; Ingrid Borecki; Janet S Rader Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-03-03 Impact factor: 4.254
Authors: Ann L Coker; Christopher P DeSimone; Katherine S Eggleston; Claudia Hopenhayn; Jaclyn Nee; Thomas Tucker Journal: Gynecol Oncol Date: 2008-11-25 Impact factor: 5.482
Authors: Yat Ming Lau; Tak Hong Cheung; Winnie Yeo; Frankie Mo; Mei Yung Yu; Kun Min Lee; Wendy C S Ho; Apple C M Yeung; Priscilla T Y Law; Paul K S Chan Journal: PLoS One Date: 2015-04-09 Impact factor: 3.240
Authors: Anthony C Nichols; Sandeep S Dhaliwal; David A Palma; John Basmaji; Corina Chapeskie; Samuel Dowthwaite; Jason H Franklin; Kevin Fung; Keith Kwan; Brett Wehrli; Chris Howlett; Iram Siddiqui; Marina I Salvadori; Eric Winquist; Scott Ernst; Sara Kuruvilla; Nancy Read; Varagur Venkatesan; Biljana Todorovic; J Alex Hammond; James Koropatnick; Joe S Mymryk; John Yoo; John W Barrett Journal: J Otolaryngol Head Neck Surg Date: 2013-02-01
Authors: Alessia Gagliardi; Vanessa L Porter; Zusheng Zong; Reanne Bowlby; Emma Titmuss; Constance Namirembe; Nicholas B Griner; Hilary Petrello; Jay Bowen; Simon K Chan; Luka Culibrk; Teresa M Darragh; Mark H Stoler; Thomas C Wright; Patee Gesuwan; Maureen A Dyer; Yussanne Ma; Karen L Mungall; Steven J M Jones; Carolyn Nakisige; Karen Novik; Jackson Orem; Martin Origa; Julie M Gastier-Foster; Robert Yarchoan; Corey Casper; Gordon B Mills; Janet S Rader; Akinyemi I Ojesina; Daniela S Gerhard; Andrew J Mungall; Marco A Marra Journal: Nat Genet Date: 2020-08-03 Impact factor: 38.330